Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 22;11:1229666. doi: 10.3389/fped.2023.1229666

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Legare and Basel.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representation of bone remodeling and the targets for therapeutic intervention. Bisphosphonates were the archetypal treatments to improve bone loss by reducing osteoclastic activity. There are several new medications that target alternate physiological pathways, but the end-point remains the same, to reduce the effect of osteoclasts. This includes newer medications under investigation which target Cathepsin K and the hydrogen pump, V-ATPase. Denausomab, Fresulimumab and Teriparatide all act by improving the osteoblast lineage.